Article info
PDFNeuromuscular
Review
Antiglycolipid antibodies in Guillain-Barré and Fisher syndromes: discovery, current status and future perspective
- Correspondence to Professor Susumu Kusunoki, Department of Neurology, Kindai University Faculty of Medicine Hospital, Osakasayama 589-8511, Japan; kusunoki-tky{at}umin.ac.jp
Citation
Antiglycolipid antibodies in Guillain-Barré and Fisher syndromes: discovery, current status and future perspective
Publication history
- Received November 16, 2020
- Revised December 14, 2020
- Accepted December 14, 2020
- First published December 29, 2020.
Online issue publication
February 12, 2021
Article Versions
- Previous version (12 February 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.